Phenylbutazone toxicity in ponies.

Seven of eight ponies given high oral doses of the NSAID phenylbutazone for 1–2 weeks developed toxicity, including loss of appetite, depression, edema, lab abnormalities, and three died of shock. Post-mortem exams showed large-intestinal submucosal edema and oral ulcers; even lower-dose IV dosing caused marked protein drops in one of two ponies.

What the study asked and why it matters

• Question: What toxic effects occur in ponies given phenylbutazone (PBZ), and how do dose and route (oral vs IV) influence risk?
• Importance: Phenylbutazone is a widely used equine NSAID; ponies are often considered more sensitive than horses, but objective data on dose-related toxicity help guide safe use.
• Clinical context: Standard equine dosing typically targets around 4.4 mg/kg/day; this study probes effects at higher oral dosing and evaluates a lower IV dose.

Study design and dosing

• Species and number: Ponies (n=10 total across both parts of the study).
• Oral cohort: 8 ponies received approximately 10 mg/kg/day of phenylbutazone for 7–14 days.
• IV cohort: 2 ponies received phenylbutazone 4.0 mg/kg intravenously daily for 7 days.
• Assessments: Clinical observation, blood biochemistry (total plasma protein, calcium, urea), and necropsy in fatal cases.

Main clinical findings

• Toxicity frequency (oral): 7/8 ponies developed signs after 7–14 days at ~10 mg/kg/day.
• Clinical signs: Anorexia (reduced appetite), depression, and abdominal (ventral) edema.
• Severe outcomes: 3 ponies died during treatment; deaths associated with shock.
• IV dosing findings: At 4 mg/kg/day for 7 days, 1/2 ponies developed a marked fall in total plasma protein, indicating risk even at lower IV dosing.

Key laboratory and pathology results

• Laboratory changes with oral dosing:
  • Decreased total plasma protein (TPP).
  • Decreased total calcium (likely reflecting calcium bound to albumin/TPP).
  • Increased blood urea concentration.
  • Authors’ interpretation: these shifts were consistent with water retention.
• Pathology (necropsy in fatal cases):
  • Prominent submucosal edema of the large intestine.
  • Oral ulceration.
  • Shock was attributed to gastrointestinal (large-intestinal) submucosal edema.

Pathophysiology and interpretation

• Mechanistic framework for NSAID toxicity in equids:
  • COX inhibition reduces protective prostaglandins in GI mucosa and kidneys.
  • GI effects: mucosal ischemia and ulceration → protein loss into the gut and edema (right dorsal colitis is a recognized syndrome with PBZ).
  • Systemic protein loss lowers oncotic pressure → ventral/abdominal edema and potential third-spacing, contributing to hypovolemia and shock.
  • Renal effects can alter fluid handling and nitrogen excretion, potentially elevating urea.
• Reconciling labs and signs:
  • Low TPP and low total calcium are compatible with dilution (water retention) and/or protein-losing enteropathy from GI injury.
  • Abdominal edema and necropsy-confirmed intestinal submucosal edema support reduced oncotic pressure and GI involvement.
  • Increased urea may reflect prerenal/renal contributions or catabolism; the authors emphasize water retention, but contemporary interpretation often highlights GI protein loss in PBZ toxicosis.
• Route and dose considerations:
  • High oral dose (~10 mg/kg/day) over 1–2 weeks produced frequent and severe toxicity.
  • IV dosing at 4 mg/kg/day still produced marked hypoproteinemia in one pony, indicating risk is not limited to oral route and that ponies may have a narrow therapeutic window.

Clinical implications for veterinarians and caretakers

• Risk in ponies:
  • Ponies appear especially susceptible to PBZ toxicity, with serious GI and systemic consequences at higher doses and with repeated dosing.
  • Even at lower IV dosing, significant protein drops can occur.
• Prudent use:
  • Use the lowest effective dose for the shortest duration; avoid exceeding commonly recommended total daily doses.
  • Prefer accurate weight-based dosing and avoid stacking with other NSAIDs or nephrotoxic/ulcerogenic drugs.
  • Ensure access to water and monitor hydration status.
• Monitoring:
  • Watch for anorexia, depression, ventral/abdominal edema, colic signs, diarrhea, or oral ulceration.
  • Check serial labs: total protein/albumin, total calcium, BUN/urea, creatinine, and potentially fecal occult blood if GI loss suspected.
  • At first signs of toxicity or falling proteins, discontinue PBZ and consider alternative analgesia and GI-protective care.
• Alternatives and mitigation:
  • Consider NSAIDs with a potentially improved GI safety profile (e.g., COX-2–selective agents like firocoxib), recognizing cross-class risks still exist.
  • Gastroprotectants and dietary management may be indicated if protein-losing enteropathy is suspected.

Limitations of the study

• Small sample size (8 oral, 2 IV) limits precision and generalizability.
• No explicit control group or randomization; observational nature within the treated cohorts.
• Short time frame; long-term outcomes and recovery trajectories not described.
• Limited laboratory panel; no albumin/TP fractionation, no direct renal diagnostics reported.

How this fits with current knowledge

• Consistent with recognized equine NSAID adverse effects: right dorsal colitis, protein-losing enteropathy, edema, oral/GI ulceration, and risk of shock.
• Supports the view that ponies may have increased sensitivity and a narrower safety margin compared to full-sized horses.
• Underscores that toxicity risk depends on dose, duration, and individual susceptibility, and that route (oral vs IV) does not eliminate risk.